Preliminary results of a phase II/III clinical study of the TLR9 agonist MGN1703 in patients with advanced colorectal carcinoma with disease control after first-line therapy: IMPACT study

Autor:	M. Schmidt, H. Schmoll, F. Mayer, J. Riera, G. Hapke, J. Andel, D. Nitsche, R. Ziebermayr, E. Weith, M. Schroff, M. Tschaika, B. Wittig
Rok vydání:	2011
Předmět:	Oncology Agonist Cancer Research medicine.medical_specialty TLR9 Agonist MGN1703 Colorectal cancer medicine.drug_class business.industry First line Impact study Pharmacology medicine.disease Internal medicine Induction therapy medicine In patient Receptor business
Zdroj:	Journal of Clinical Oncology. 29:e14114-e14114
ISSN:	1527-7755 0732-183X
Popis:	618 Background: MGN1703 is a synthetic DNA-based immunomodulator, which acts as an agonist of toll-like receptor 9. The antineoplastic activity of MGN1703 was previously shown in several in-vitro a...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::c7c4c50c2953556a27c2b317883255f6 https://doi.org/10.1200/jco.2011.29.15_suppl.e14114 Zobrazit plný text záznamu